Table 1 Characteristics of 47 enrolled patients.
From: Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients
Characteristics | All patients (N = 47) | Recovered (N = 35) | Dead (N = 12) |
|---|---|---|---|
Age, median (range) | 59 (33–82) | 55 (33–77) | 64 (53–82) |
Sex | |||
Male | 29/47 (61.7) | 21/35 (60) | 8/12 (66.67) |
Female | 18/47 (38.3) | 14/35 (40) | 4/12 (33.33) |
Clinical severity | |||
Mild | 10/47 (21.28) | 10/35 (28.57) | 0 |
Severe | 37/47 (78.72) | 25/35 (71.43) | 12 (100) |
Symptoms | |||
Fever | 39/47 (82.98) | 31/35 (88.57) | 8/12 (66.67) |
Dry cough | 39/47 (82.98) | 31/35 (88.57) | 8/12 (66.67) |
Dyspnea | 34/47 (72.34) | 25/35 (71.43) | 9/12 (75) |
Myalgia | 20/47 (42.55) | 16/35 (45.71) | 4/12 (33.33) |
Acute respiratory insufficiency | 10/47 (21.28) | 7/35 (20) | 3/12 (25) |
Headache | 6/47 (12.77) | 6/35 (17.14) | 0 |
Thromboembolism | 5/47 (10.64) | 4/35 (11.43) | 1/12 (8.33) |
Diarrhea | 4/47 (8.52) | 3/35 (8.57) | 1/12 (8.33) |
Pneumonia | 3/47 (6.39) | 3/35 (8.57) | 0 |
Chill | 2/47 (4.26) | 1/35 (2.86) | 1/12 (8.33) |
Asthenia | 2/47 (4.26) | 1/35 (2.86) | 1/12 (8.33) |
Odynophagia | 1/47 (2.13) | 1/35 (2.86) | 0 |
Nasal obstruction | 1/47 (2.13) | 1/35 (2.86) | 0 |
Respiratory distress | 1/47 (2.13) | 1/35 (2.86) | 0 |
Dysuria | 1/47 (2.13) | 1/35 (2.86) | 0 |
Sweating | 1/47 (2.13) | 1/35 (2.86) | 0 |
Anosmia | 1/47 (2.13) | 1/35 (2.86) | 0 |
Sore throat | 1/47 (2.13) | 1/35 (2.86) | 0 |
Malaise | 1/47 (2.13) | 0 | 1/12 (8.33) |
Hyporexia | 1/47 (2.13) | 0 | 1/12 (8.33) |
Coexisting disorders | |||
Obesity | 25/47 (53.19) | 17/35 (48.57) | 8/12 (66.67) |
Hypertension | 23/47 (48.94) | 17/35 (48.57) | 6/12 (50) |
Diabetes | 16/47 (30.04) | 11/35 (31.43) | 5/12 (41.67) |
HIV | 3/47 (6.39) | 2/35 (5.71) | 1/12 (8.33) |
Deep vein thrombosis | 3/47 (6.39) | 2/35 (5.71) | 1/12 (8.33) |
COPD | 3/47 (6.39) | 2/35 (5.71) | 1/12 (8.33) |
Hypothyroidism | 2/47 (4.26) | 1/35 (2.86) | 1/12 (8.33) |
Prostatic hypertrophy | 2/47 (4.26) | 1/35 (2.86) | 1/12 (8.33) |
Stroke | 2/47 (4.26) | 1/35 (2.86) | 1/12 (8.33) |
Asthma | 2/47 (4.26) | 2/35 (5.71) | 0 |
Pre-existing lesions | 1/47 (2.13) | 1/35 (2.86) | 0 |
Tinea cruris | 1/47 (2.13) | 1/35 (2.86) | 0 |
Sleep apnea | 1/47 (2.13) | 1/35 (2.86) | 0 |
Epilepsy | 1/47 (2.13) | 1/35 (2.86) | 0 |
Hepatitis B | 1/47 (2.13) | 1/35 (2.86) | 0 |
Encephalitis | 1/47 (2.13) | 1/35 (2.86) | 0 |
Cardiac insufficiency | 1/47 (2.13) | 1/35 (2.86) | 0 |
Kidney transplant | 1/47 (2.13) | 1/35 (2.86) | 0 |
None | 4/47 (8.52) | 4/35 (11.43) | 0 |
Treatment | |||
Antibiotics | 45/47 (95.74) | 33/35 (94.29) | 12 (100) |
Antiviral | 24/47 (51.06) | 17/35 (48.57) | 7/12 (58.33) |
Corticoids | 16/47 (30.04) | 12/35 (34.29) | 4/12 (33.33) |
Anticoagulants | 13/47 (27.67) | 10/35 (28.57) | 3/12 (25) |
Chloroquine | 9/47 (19.15) | 7/35 (20) | 2/12 (16.67) |
Immunosuppressant | 1/47 (2.13) | 1/35 (2.86) | 0 |
Vasodilator | 1/47 (2.13) | 1/35 (2.86) | 0 |
